SCG Cell Therapy Partners with A*STAR BTI and NATi to Advance RNA-Based Therapeutics

Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Cartherics Receives $300K G-Rex Grant to Advance Cancer Cell Therapy Manufacturing

Home
/
update
/
details

Immuneel Therapeutics Appoints Amit Mookim as New CEO

NextEdge Admin

17 Sep 2024

2 min 15 sec

Chief Executive Officer,immunotherapy,Leadership

Immuneel Therapeutics is pleased to announce the appointment of Amit Mookim as Chief Executive Officer. With over 20 years of experience across life sciences, technology, and private equity, Amit is set to lead the next phase of growth and innovation for Immuneel in the cell and gene therapy space.

Amit joins Immuneel from IQVIA, where he served as Managing Director for South Asia, leading a team of over 20,000 professionals and driving significant commercial growth. Previously, he headed healthcare at KPMG India, where he helped establish and expand the firm’s healthcare practice, advising hospitals, private equity funds, and global healthcare companies.

A recognized thought leader, Amit has advised the National Health Authority on startup market access under the PMJAY scheme and worked with industry organizations like the Indian Pharmaceutical Alliance, APACMED, and FICCI. He has also contributed to leadership initiatives on universal healthcare, innovation, and regulatory collaborations across South Asia, APAC, the Middle East, and Europe.

Under his leadership, Immuneel will focus on expanding access to its CAR-T therapies, building global partnerships, and enhancing its presence in India and internationally. Co-founders Dr. Kiran Mazumdar-Shaw, Dr. Siddhartha Mukherjee, and Dr. Kush Parmar are confident in Amit’s ability to guide the company’s mission of transforming cancer care.

The Immuneel team welcomes Amit as they continue to break new ground in cancer immunotherapy for patients in India and beyond.